Pfizer: new positive study on Ibrance

(CercleFinance.com) - Pfizer today announced that it will present concrete evidence demonstrating the efficacy of Ibrance (palbociclib) in combination with an aromatase inhibitor (AI), compared to AI alone, at the 2022 Congress of ESMO, the European Society for Medical Oncology.


A large comparative efficacy study of 2,888 patients with HR+ and HER2-positive metastatic breast cancer (mBC) indeed demonstrated improved overall survival (OS) in postmenopausal women and men who were treated with Ibrance + AI.

Since its approval, Ibrance has generated promising results for adults diagnosed with HR+, HER2- and this latest analysis reflects Pfizer's commitment to using real-world evidence to complement its traditional randomised clinical trials, an oncology specialst at Pfizer said.


Copyright (c) 2022 CercleFinance.com. All rights reserved.